160 related articles for article (PubMed ID: 34781928)
1. Nomogram to predict survival of patients with advanced and metastatic pancreatic Cancer.
Deng GC; Lv Y; Yan H; Sun DC; Qu TT; Pan YT; Han QL; Dai GH
BMC Cancer; 2021 Nov; 21(1):1227. PubMed ID: 34781928
[TBL] [Abstract][Full Text] [Related]
2. Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study).
Shibuki T; Mizuta T; Shimokawa M; Koga F; Ueda Y; Nakazawa J; Komori A; Otsu S; Arima S; Fukahori M; Makiyama A; Taguchi H; Honda T; Mitsugi K; Nio K; Ide Y; Ureshino N; Shirakawa T; Otsuka T
BMC Cancer; 2022 Jan; 22(1):19. PubMed ID: 34980029
[TBL] [Abstract][Full Text] [Related]
3. Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
Takumoto Y; Sasahara Y; Narimatsu H; Akazawa M
JAMA Netw Open; 2022 Jan; 5(1):e2145515. PubMed ID: 35099549
[TBL] [Abstract][Full Text] [Related]
4. Nomograms predicting survival of patients with unresectable or metastatic gastric cancer who receive combination cytotoxic chemotherapy as first-line treatment.
Kim SY; Yoon MJ; Park YI; Kim MJ; Nam BH; Park SR
Gastric Cancer; 2018 May; 21(3):453-463. PubMed ID: 28828688
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy.
An X; Li YH; Lin XB; Wang FH; Feng F; Xu RH; Jiang WQ; He YJ
Ai Zheng; 2009 Mar; 28(3):286-91. PubMed ID: 19619444
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Clinical Predictive Factors Affecting the Outcome of Second-Line Chemotherapy for Gemcitabine-Refractory Advanced Pancreatic Cancer.
Lee JE; Lee HS; Chung MJ; Park JY; Park SW; Song SY; Bang S
Gut Liver; 2020 Jan; 14(1):135-143. PubMed ID: 30974927
[No Abstract] [Full Text] [Related]
7. Efficacy and safety comparison of nabpaclitaxel plus S-1 and gemcitabine plus S-1 as first-line chemotherapy for metastatic pancreatic cancer.
Xu Y; Guo X; Fan Y; Wang D; Wu W; Wu L; Liu T; Xu B; Feng Y; Wang Y; Lou W; Zhou Y
Jpn J Clin Oncol; 2018 Jun; 48(6):535-541. PubMed ID: 29718363
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer.
Maréchal R; Demols A; Gay F; De Maertelaere V; Arvanitaki M; Hendlisz A; Van Laethem JL
Oncology; 2007; 73(1-2):41-51. PubMed ID: 18334830
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Predicting Role of Contrast-Enhanced Computed Tomography for Locally Advanced Pancreatic Adenocarcinoma.
Cheng CS; Liu W; Zhou L; Tang W; Zhong A; Meng Z; Chen L; Chen Z
Biomed Res Int; 2019; 2019():1356264. PubMed ID: 31886169
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study.
Inal A; Kos FT; Algin E; Yildiz R; Berk V; Tugba Unek I; Colak D; Colak D; Kucukoner M; Tamer Elkiran E; Helvaci K; Geredeli C; Dane F; Balakan O; Ali Kaplan M; Gok Durnali A; Harputoglu H; Goksel G; Ozdemir N; Buyukberber S; Gumus M; Ozkan M; Benekli M; Isikdogan A;
J BUON; 2012; 17(1):102-5. PubMed ID: 22517701
[TBL] [Abstract][Full Text] [Related]
11. Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study.
Zong Y; Yuan J; Peng Z; Lu M; Wang X; Shen L; Zhou J
J Cancer Res Clin Oncol; 2021 May; 147(5):1529-1536. PubMed ID: 33191450
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study.
Fernández A; Salgado M; García A; Buxò E; Vera R; Adeva J; Jiménez-Fonseca P; Quintero G; Llorca C; Cañabate M; López LJ; Muñoz A; Ramírez P; González P; López C; Reboredo M; Gallardo E; Sanchez-Cánovas M; Gallego J; Guillén C; Ruiz-Miravet N; Navarro-Pérez V; De la Cámara J; Alés-Díaz I; Pazo-Cid RA; Carmona-Bayonas A
BMC Cancer; 2018 Nov; 18(1):1185. PubMed ID: 30497432
[TBL] [Abstract][Full Text] [Related]
13. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
[TBL] [Abstract][Full Text] [Related]
14. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG
JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of a prognostic nomogram to predict survival in patients with advanced pancreatic cancer receiving second-line palliative chemotherapy.
Hsu CC; Liu KH; Chang PH; Chen PT; Hung CY; Hsueh SW; Yeh KY; Chen YY; Lu CH; Hung YS; Chou WC
J Gastroenterol Hepatol; 2020 Oct; 35(10):1694-1703. PubMed ID: 31711261
[TBL] [Abstract][Full Text] [Related]
16. Nomogram for Estimating Overall Survival in Patients With Metastatic Pancreatic Cancer.
Goldstein D; Von Hoff DD; Chiorean EG; Reni M; Tabernero J; Ramanathan RK; Botteman M; Aly A; Margunato-Debay S; Lu B; Louis CU; McGovern D; Lee CK
Pancreas; 2020 Jul; 49(6):744-750. PubMed ID: 32541630
[TBL] [Abstract][Full Text] [Related]
17. Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma.
Vienot A; Beinse G; Louvet C; de Mestier L; Meurisse A; Fein F; Heyd B; Cleau D; d'Engremont C; Dupont-Gossart AC; Lakkis Z; Tournigand C; Bouché O; Rousseau B; Neuzillet C; Bonnetain F; Borg C; Vernerey D
J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 28383673
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
Li Y; Sun J; Jiang Z; Zhang L; Liu G
J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948
[TBL] [Abstract][Full Text] [Related]
19. A Chinese Retrospective Multicenter Study of First-Line Chemotherapy for Advanced Pancreatic Cancer.
Cui H; Guan J; Deng G; Yuan J; Lou C; Zhang W; Zhou A; Zhang Y; Zhou J; Dai G
Med Sci Monit; 2020 Oct; 26():e927654. PubMed ID: 33100319
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of S-1 in second-line chemotherapy after nab-paclitaxel plus gemcitabine for patients with advanced pancreatic cancer.
Iede K; Yamada T; Kato R; Ueda M; Tsuda Y; Nakashima S; Ohta K; Matsuyama J; Ikenaga M; Tominaga S
Cancer Rep (Hoboken); 2020 Apr; 3(2):e1215. PubMed ID: 32672000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
